Galderma SA is a global dermatology company headquartered in Switzerland that develops, manufactures, and markets medical and aesthetic skin health products. Established in 1981, it operates across R&D, production, and commercial functions with a presence in major regions worldwide.
The company’s portfolio spans three areas: injectable aesthetics (including hyaluronic acid dermal fillers and biostimulatory injectables, as well as botulinum toxin type A for aesthetic use), dermo-cosmetics for daily skin care (such as the Cetaphil range), and prescription dermatology targeting conditions like acne and rosacea. Galderma serves dermatologists, aesthetic practitioners, pharmacies, and consumers in more than 100 countries, with a focus on evidence-based products and large-scale manufacturing for skin health applications.
Successor returns July 1 as EVP and assumes CFO duties Sept 1; outgoing CFO stays through Jan 2027 to aid transition. Successor has 30+ yrs finance leadership, ex‑CFO at Galderma, Shire, Sulzer.
Merck forms Oncology and Specialty units, appoints new leaders, and aims to boost commercial success and pipeline execution.
